TICKERNERD
Menu
QTRXQTRXHealthcare · Medical Devices

QTRX Stock Forecast: Quanterix Corp. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$3.21
−3.46% on the day

The 3 Wall Street analysts covering Quanterix Corp. hold a median 12-month price target of $3 — -6.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$162.7M
Ticker Nerd rank
28 / 100
Median analyst target
$3.00
Analysts covering
3
Revenue$32.9M+34.6% y/y
Operating income−$22.5M
Net income−$48.9M
Free cash flow−$5.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.9%
1M
+17.6%
YTD
−49.5%
1Y
−46.5%
From 52W high
−60.2%
From 52W low
+32.6%
$2.42
$8.06
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

QTRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Quanterix Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
71
Growth
58
Accruals
53
Issuance
49
Quality
41
Value
38
Volatility
37
Revisions
26
Momentum
15

Size (71): Smaller than most of the companies we track.

Momentum (15): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

QTRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QTRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00$6.00$7.00$8.00Jan 26Apr 26Jul 26Oct 26QTRXHigh $3.00Median $3.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
0 Buy3 Hold0 Sell
Low $3.00Median $3.00High $3.00

The green dot is the last close — the median target sits −6.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
17 Aug 2026Canaccord GenuityMaintainsHold$4.00 → $3.00
11 Aug 2026TD CowenMaintainsHold$4.00 → $3.00
7 May 2026TD CowenMaintainsHold$7.00 → $4.00
7 May 2026TD CowenMaintainsHold—
20 Apr 2026Canaccord GenuityMaintainsHold—
22 Dec 2025Canaccord GenuityMaintainsHold—
11 Aug 2025Canaccord GenuityDowngradeHold—
13 May 2025Canaccord GenuityMaintainsBuy—
30 Apr 2025Leerink PartnersDowngradeMarket Perform—
25 Mar 2025ScotiabankMaintainsSector Outperform—
18 Mar 2025Canaccord GenuityMaintainsBuy—
13 Nov 2024TD CowenMaintainsHold—
12 Aug 2024ScotiabankMaintainsSector Outperform—
9 Aug 2024TD CowenMaintainsHold—
9 July 2024Goldman SachsMaintainsBuy—
29 Apr 2024Canaccord GenuityMaintainsBuy—
4 Mar 2024ScotiabankMaintainsSector Outperform—
28 Sept 2023Goldman SachsMaintainsBuy—
27 Sept 2023Goldman SachsMaintainsBuy—
25 Sept 2023Canaccord GenuityUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QTRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

QTRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Quanterix Corp. returned −46.5% against +16.2% for the S&P 500, dividends included.

QTRX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26QTRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

QTRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Quanterix Corp. (QTRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.4×

Cheaper than 84% of US stocks

Price / sales
1.1×

Cheaper than 67% of US stocks

Price / book
0.7×

Cheaper than 80% of US stocks

EV / EBITDA
−1.7×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
34.4%

Higher than 80% of US stocks

Earnings growth (YoY)
34.6%

Higher than 68% of US stocks

Gross margin
38.5%

Higher than 47% of US stocks

Operating margin
−68.4%

Higher than 15% of US stocks

Net margin
−80.2%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−46.5%

Higher than 22% of US stocks

Return on assets
−16.7%

Higher than 22% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Quanterix Corp. (QTRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Quanterix Corp. has a market value of $162.7M and an enterprise value of $120.0M.

  • Revenue in the twelve months to 30 June 2026: $153.2M. The latest quarter grew 34.4% year on year.

  • Net income over the same four quarters: −$123.1M, a −80.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.63.

  • Free cash flow in the twelve months to 30 June 2026: −$81.7M.

  • Shares outstanding: 47.1M.

  • Trailing P/E: −1.4×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Quanterix Corp. employs 450 people — $341K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

QTRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
QTRXQuanterix Corp.$162.7M
28
INGNInogen, Inc.$161.8M
81
STIMNeuronetics, Inc.$163.1M
66
OWLTOwlet, Inc.$135.1M
39
LUCDLucid Diagnostics, Inc.$132.0M
35
RXSTRxSight, Inc.$200.8M
41
MXCTMaxCyte, Inc.$109.3M
75

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Quanterix Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest QTRX news & analysis

Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals

Business Wire · 7 Oct 2026positive

Quanterix and Innovita announced regulatory approvals from China’s National Medical Products Administration to expand access to Quanterix SIMOA technology and neurology biomarker testing in China. The companies’ commercialization arrangement was initially formed in 2024.

Why it matters — The approvals represent progress in expanding access to Quanterix’s technology and testing through its arrangement with Innovita in the Chinese market.

Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026

Business Wire · 25 Sept 2026positive

Quanterix reported progress on its Content Innovation Engine at the European Society for Spatial Biology meeting on September 28-October 1, 2026, updating initiatives originally introduced at the AACR Annual Meeting 2026. The company highlighted its growing leadership in spatial biology content, delivering assays for researchers.

Why it matters — QTRX watchers would care because the company is demonstrating delivery on its spatial biology content innovation commitments, reinforcing its competitive position and growth in that market.

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 17 Sept 2026neutral

Quanterix Corporation announced inducement grants made on September 15, 2026 under Nasdaq Listing Rule 5635(c)(4) to newly appointed Chief Commercial Officer James Gute, consisting of 260,315 restricted stock units, and to two other employees in connection with the commencement of their employment.

Why it matters — This reporting of equity grants provides transparency to QTRX watchers about executive compensation tied to the hiring of the new Chief Commercial Officer.

Quanterix Names Dr. Yuri Fesko Chief Medical Officer

Business Wire · 14 Sept 2026positive

Quanterix Corporation announced that Dr. Yuri Fesko has been appointed Chief Medical Officer, where he will provide medical and clinical leadership across the company, working with Diagnostics, Scientific, R&D, Regulatory, and Commercial teams to advance Quanterix's technologies and applications.

Why it matters — A QTRX watcher would care because adding a physician executive to the leadership team signals strengthened medical and clinical expertise across the company's diagnostic and R&D efforts.

Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer's Blood Test

MarketBeat · 16 Aug 2026neutral

Quanterix CEO Everett Cunningham said the company is repositioning its commercial organization and investing in diagnostics and clinical-trial capabilities following the integration of Akoya Biosciences. He also acknowledged continued market pressure in academic, government and biopharma segments.

Why it matters — QTRX watchers would care because the company is restructuring its sales strategy and hinting at a possible Q4 FDA decision for its Alzheimer's blood test amid persistent demand headwinds in key markets.

FAQ

Frequently asked questions about QTRX stock

What is the QTRX stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Quanterix Corp. have a median 12-month price target of $3, with estimates ranging from $3 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QTRX stock a buy right now?

Of the 3 analysts covering Quanterix Corp., 0 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Quanterix Corp. 28 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QTRX?

As at 8 Oct 2026, Quanterix Corp. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (71 of 100).

Will QTRX stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies -6.5% from the last close, and Ticker Nerd's factor model ranks Quanterix Corp. 28 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QTRX stock forecast for 2030?

No analyst covering Quanterix Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QTRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $3 over the next 12 months.

How has QTRX stock performed over the past year?

Quanterix Corp. returned -46.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Quanterix Corp. do?

Quanterix Corporation is a life sciences tools and diagnostics company that develops ultra-sensitive digital immunoassay platforms for research and clinical applications. Quanterix’s core products and services include the Simoa assay kits, automated analyzers, biomarker detection systems, imaging and analysis platforms, and laboratory services used to measure very low levels of proteins and other biomarkers in blood and related fluids.

What is the latest news on QTRX?

The most recent item we track (Business Wire, 7 Oct 2026): "Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals". Quanterix and Innovita announced regulatory approvals from China’s National Medical Products Administration to expand access to Quanterix SIMOA technology and neurology biomarker testing in China. The companies’ commercialization arrangement was initially formed in 2024.

Company

About Quanterix Corp.

Quanterix Corporation is a life sciences tools and diagnostics company that develops ultra-sensitive digital immunoassay platforms for research and clinical applications. Quanterix’s core products and services include the Simoa assay kits, automated analyzers, biomarker detection systems, imaging and analysis platforms, and laboratory services used to measure very low levels of proteins and other biomarkers in blood and related fluids. The company supports work across disease research, diagnostics, and drug development, helping laboratories and healthcare organizations generate precise biomarker data for scientific and clinical use. Quanterix serves customers in North America, Europe, the Middle East, Africa, and the Asia Pacific regions, with offerings used by academic researchers, biopharmaceutical companies, and clinical laboratories. Founded in 2007 and headquartered in Billerica, Massachusetts, Quanterix Corporation plays a specialized role in precision biomarker science and advanced diagnostic testing.

CEO Mr. Everett V. Cunningham · 450 employees · United States · https://www.quanterix.com